The therapeutic efficacy of recombinant human leukemia inhibitory factor (LIF) was examined in a nonhuman primate model of radiation-induced marrow aplasia. Rhesus monkeys received 450 cGy of total-body, 1:l mixed neutron:gamma radiation. For 23 days thereafter, each monkey received a daily subcutaneous injection of LIF or human serum albumin (HSA) at a dose of I S pg/kg body weight. Complete blood counts and white blood cell differentials were monitored for 60 days postirradiation. Administration of LIF significantly decreased (P I .05) the duration of thrombocy-HROMBOCYTOPENIA and neutropenia remain as dose-limiting consequences after high-dose irradiation or cytotoxic drug exposure. Cytokines such as recombinant human granulocyte and granulocyte-macrophage colonystimulating factor have been effective in reducing the duration of neutropenia after radiation-or drug-induced marrow aplasia in preclinical"6 and clinical proto~ols.~-~ Several cytokines have shown therapeutic efficacy in modulating the recovery of platelets after or drug-induced marrow ap1a~ia.ll-l~ Interleukin-3 (E-3) has shown a modest yet consistent efficacy in preclinical models of myelosuppression6." but has demonstrated variable efficacy in modulating thrombocytopenia in the clinical situation.14"* More recently, IL-6 has displayed efficacy in reducing thrombocytopenia and enhancing recovery of platelets in r n~r i n e ,~~. '~-~~ canine,23 and models of either radiation-or drug-induced thrombocytopenia. Results from clinical trials with IL-6 have shown it to be efficacious in modulating drug-induced thrombo~ytopenia.~~.'~ IL-11 has also been shown to enhance the recovery of platelets in several murine models of myelosupp r e s s i~n .~~~~~ Yet another cytokine, leukemia inhibitory factor (LIF),
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has recently been shown to promote megakaryocyte maturation in and to increase circulating levels of platelets in normal mice35 and nonhuman primates. 36 The purpose of this study was to investigate the therapeutic efficacy of LIF in a high-dose, sublethal, primate model of radiation-induced marrow aplasia. vector. The in vitro biologic activity of the recombinant human LIF (rhLIF) was analyzed in a proliferation assay of the DA1 murine leukemia cell line and was approximately 13 X IO6 U/mg protein.
T MATERIALS AND METHODS

Animals
The units were calculated on the basis that 1 U of LIF was able to induce 50% of maximal proliferation. The endotoxin content was 10.6 EU/mg of LIF as determined by the Limulus assay3' (Limulus amoebocyte lysate assay; Bio Whittaker, Inc, Walkersville, MD).
Irradiation. After a prehabituation period, each monkey was placed in an aluminum restraining chair and subjected to posteriorto-anterior total-body irradiation from the AFRRI Mark-F "RIGA nuclear reactor. The torso of each monkey was shielded from the intense gamma radiation emitted by placing a 2.5-cm lead shield between the core of the reactor and the exposure position. Each monkey received a pulse of 4.5 Gy (< 500 milliseconds) free-inair total mixed neutrons and gamma rays with a precision of 22.5% (%SD, n = 16) and a statistical accuracy of 10%. The neutron dose to the total dose (neutron + gamma) was 0.50% 2 2.3% (%SD, n = 17), with a statistical accuracy of 14%. All exposures were actively monitored by ionization chambers and passively monitored by sulfur activation tablets.
Study design. Each animal was irradiated on day 0 and randomly assigned to receive either LIF (n = 4) or human serum albumin (HSA; n = 5; Miles Inc, Cutter Biological, Elkhart, IN). LIF or HSA were administered as a single, subcutaneous injection at a dosage of 15 pg/kg/day. The dosage and administration route were based on results shown in normal rhesus primates by Mayer et a1, 36 in which efficacy at platelet production without toxicity was evident at 10 pg/kg/d for 14 days.
Support. An antibiotic regimen was initiated prophylactically when the white blood cell count was less than l,OOO/pL and continued daily until the white blood cell count was greater than 1,OOO/ pL for 3 consecutive days. Gentamicin (Lyphomed, Deerfield, IL; 1.5 mgkg, twice daily) and rocephin (Roche, Nutley, NJ; 100 mg/ kg/d) were administered subcutaneously. Fresh, irradiated (1,500 cGy CO-60) whole blood from a random donor pool ( IN) . Baseline levels were obtained before irradiation. These parameters were monitored for 60 days after irradiation and the degree of anemia and the durations of neutropenia (absolute neutrophil count <l,OOO//*L) and thrombocytopenia (platelet count either <30,000 or 20,OOO/pL) were assessed.
Statistical analysis. The Normal Scores Test was used to make painvise comparisons of the durations of neutropenia and thrombocytopenia. The test was performed using the software package StatXact (Cytel Software Corp, Cambridge, MA) and exact P values were obtained. The Mann Whitney test was used to evaluate the statistical difference between the nadirs.
RESULTS
Platelet and neutrophil recovery. LIF administration induced recovery of circulating platelets to baseline values, without lessening the nadir, earlier than did HSA treatment (day 22 v day 32, respectively; Fig 1A) . LIF administration, compared with HSA treatment, also significantly decreased the duration of thrombocytopenia either at a platelet count less than 30,000 or 20,OOO/pL ( P 5 .05) to 9 days or 6.3 days v 12 days or 10.2 days, respectively (Fig 1A and Table   1 Monkeys receiving whole body irradiation with 450 cGy of mixed fission:neutron gamma radiation were treated with control protein (HSA) or LIF according to protocol. Neutropenia is an absolute neutrophil count of less than l,OOO/pL. Thrombocytopenia is either a platelet count of less than 20,000 or 30,00O/pL. * P c .05. 1). Although neither the duration of neutropenia nor the recovery of neutrophils in the LIF-treated monkeys differed from those in HSA-treated monkeys, the period of absolute neutropenia was modified by LIF administration (Fig 1B and Table 1 ).
Anemia. LIF did not exacerbate the radiation-induced anemia noted in HSA-treated monkeys (Fig 2) . Mean hemoglobin (HGB) values were lower in the HSA-treated monkeys, although there was no significant difference in the respective HGB nadirs. The HGB values in the LIF-treated monkeys returned to within baseline levels more quickly (day 48) than in the HSA-treated monkeys (day 70). All animals did not require transfusions; the HSA-treated animals required an average of two transfusions per animal, whereas the LIF-treated animals received less than one transfusion per animal.
DISCUSSION
We have shown that the therapeutic administration of LIF, as compared with HSA, to sublethally irradiated monkeys can induce an earlier recovery of circulating platelets to normal levels and can signifiantly reduce the duration of thrombocytopenia. The return to normal circulating platelet levels is the result of the apparent increase in production rate of platelets during week 3 of LIF administration. This finding is concordant with results in normal primates receiving LIF36 in which the onset of platelet production occurred at the end of a 14-day administration period. The number and size of megakaryocytes in the bone marrow of the normal primates did not change. However, recombinant murine LIF administered to normal mice increased both megakaryocyte and progenitor cells in marrow and spleen and resulted in an almost twofold increase in the circulating platelet count."
Using the same radiation model as reported here, we recently described the therapeutic efficacy of IL-3 and IL-6 in promoting platelet and neutrophil production.2s In our previous report, L -3 and IL-6 reduced the duration of thrombocytopenia from 12 days in the controls to 6.6 days and 5 days, re~pectively.~~ IL-3 and IL-6 were used at the same dose (15 pg/kg/d) and protocol as reported here.
The therapeutic efficacy of LIF was suggested by data showing the shared gp130 signal transducing component with IL-6, IL-11, and Oncostatin-M:' in addition to in vitro studies with murine and human bone marrow cell cult u r e~.~~.~~ Metcalf et a13' showed that LIF increased megakaryocyte colony formation and megakaryocytes when used in combination with IL-3. LIF alone had no demonstrable direct effect on these parameters despite the presence of LIF receptors on both immature and mature murine megakayocytes. Burstein et a134 compared LIF with IL-6 and IL-1 1 and found that LW promoted megakaryocyte maturation in both liquid murine and human marrow cultures but did not induce an increase in megakaryocyte number in the absence of IL-3. This LIF-induced response did not appear to be facilitated through IL-6 action because the presence of an anti-IL-6 antibody had no influence on the LIF-induced increase in ploidy. However, LIF has been shown to induce synthesis and release of biologically active IL-6 from monocytes. 39 Leary et ala also showed that LIF in combination with IL-3 enhanced human marrow-derived blast-cell colony formation.
The lack of an LIF-induced production of neutrophils noted in this model of radiation-induced marrow aplasia agrees with that observed in normal animals. Daily injections of LIF into normal mice3' or primates36 had no influence on total and differential leukocyte counts. In a previous study of radiation-induced marrow aplasia in the primate, we showed that neither IL-6 nor IL-3 significantly altered the duration of neutropenia or the recoveq of neutrophils but, as currently shown with LIF, did modify the neutropenic nadir, relative to HSA-treated control^.^'
These results show that LIF may be effective in the treatment of radiation-induced thrombocytopenia. This effect may be mediated in part through the concomitant presence of endogenous IL-3, IL-6, or other complementary cytokines in the postirradiation marrow environment. 
